Research Overview
· Last Reviewed May 3, 2026· PSI Editorial Board· IndependentCan Peptides Help With Type 2 Diabetes?
The honest map across 8 type 2 diabetes scenarios — what is FDA-approved, what is in Phase 3, and where validated metformin and standard-of-care rule.
WHICH T2D CONTEXT?
T2D Context
Animal Studies
Human Trials
T2D glycemic control with cardiovascular risk
FDA-approved CV outcomes indication
T2D wanting maximum HbA1c reduction
FDA-approved Mounjaro indication
T2D first-line pharmacotherapy
metformin per ADA Standards of Care
T2D with established CV disease
FDA-approved CV outcomes indication
T2D with chronic kidney disease
SGLT2 inhibitor + GLP-1 RA validated
Pediatric T2D adolescents 10 years and older
FDA-approved Liraglutide pediatric indication
T2D oral therapy preference
FDA-approved Rybelsus indication
Phase 3 triple-agonist research access
investigational class context
How counts are scaled → · Tap any row to see the studies →
Quick Answer
Type 2 diabetes has well-characterized validated approaches in clinical practice. Foundations include comprehensive evaluation by endocrinology or primary care. Workup covers HbA1c, fasting glucose, lipid panel, and metabolic panel per ADA Standards of Care. Additional assessment includes cardiovascular risk evaluation and complication screening.
Semaglutide anchors the FDA-approved GLP-1 receptor agonist class for T2D. The compound holds FDA approval as Ozempic for type 2 diabetes and Rybelsus as oral formulation. Phase 3 SUSTAIN program supported approvals.
Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes. The compound is a dual GIP/GLP-1 receptor agonist with Phase 3 SURPASS evidence demonstrating superior HbA1c reduction.
Liraglutide is FDA-approved as Victoza for type 2 diabetes. The compound has pediatric T2D indication for adolescents 10 years and older.
Retatrutide is investigational with Phase 3 TRIUMPH-2 program at Eli Lilly. The compound is a triple GLP-1/GIP/glucagon receptor agonist studying T2D applications.
The honest framing: three peptides hold FDA approvals for type 2 diabetes with substantial Phase 3 evidence. Validated metformin first-line and multi-class standard-of-care remain foundational per ADA Standards of Care. For broader context, see Peptides for Metabolic Health, Peptides for Insulin Resistance, and Peptides for Cardiovascular Health.
Semaglutide vs Tirzepatide for T2D
Two FDA-approved GLP-1-class therapies in head-to-head SURPASS-2
Semaglutide is FDA-approved as Ozempic for T2D with substantial Phase 3 SUSTAIN program evidence. Mechanism is GLP-1 receptor agonism with glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central appetite reduction. HbA1c reduction is approximately 1.5 to 2.0 percent. SUSTAIN-6 cardiovascular outcomes trial demonstrated benefits in T2D with established CV disease. Once-weekly subcutaneous dosing is convenient. Oral Rybelsus formulation provides alternative for patients preferring oral therapy.
Tirzepatide is FDA-approved as Mounjaro for T2D with Phase 3 SURPASS program evidence. Mechanism is dual GIP/GLP-1 receptor agonism with potential for additive metabolic effects. HbA1c reduction is approximately 2.0 to 2.5 percent. SURPASS-2 head-to-head trial demonstrated superior HbA1c reduction versus Semaglutide over 40 weeks. SURPASS-CVOT cardiovascular outcomes trial is ongoing. Once-weekly subcutaneous dosing matches Semaglutide convenience.
PSI's reading: both compounds hold FDA approvals for T2D with substantial Phase 3 evidence. Tirzepatide demonstrates superior HbA1c reduction in SURPASS-2 head-to-head. Semaglutide has earlier cardiovascular outcomes evidence (SUSTAIN-6, SELECT) and oral formulation availability. Patient selection considers individualized factors, cardiovascular risk, formulation preference, and access under endocrinology or primary care guidance per ADA Standards of Care. Both are appropriate validated options.
GLP-1 receptor agonists vs metformin first-line for T2D
Established first-line versus newer-generation pharmacotherapy
Metformin is the FDA-approved first-line pharmacotherapy for T2D per ADA Standards of Care. Mechanism includes hepatic gluconeogenesis suppression, intestinal glucose absorption reduction, and insulin sensitivity improvement. Phase 3 evidence and decades of safety data support the indication. Cost is low with generic availability. Cardiovascular safety is established. Common side effects include GI symptoms during initiation. Vitamin B12 deficiency monitoring is appropriate during long-term use. The compound is the cornerstone of T2D pharmacotherapy.
GLP-1 receptor agonists including Semaglutide, Tirzepatide, and Liraglutide are FDA-approved with substantial Phase 3 evidence for T2D glycemic control. The class typically achieves greater HbA1c reduction than metformin monotherapy. Cardiovascular outcomes benefits are established for select compounds in T2D with established CV disease. Renal outcomes benefits are established for Semaglutide in T2D with chronic kidney disease (FLOW trial).
PSI's reading: metformin remains validated first-line per current ADA Standards of Care for most T2D patients. GLP-1 receptor agonists are appropriate as add-on therapy or first-line for patients with established CV disease, high CV risk, chronic kidney disease, or obesity where guidelines support GLP-1 RA preference. Combination therapy is common in clinical practice. Endocrinology or primary care guidance ensures appropriate matching to individualized factors.
GLP-1 RAs vs SGLT2 inhibitors for T2D
Two validated FDA-approved classes with cardiovascular and renal outcomes
GLP-1 receptor agonists including Semaglutide and Liraglutide are FDA-approved for T2D with cardiovascular outcomes indications in select populations. Mechanism is incretin signaling with glycemic, weight, and cardiovascular effects. HbA1c reduction is approximately 1.0 to 2.5 percent depending on compound. Weight reduction is typically observed. SUSTAIN-6, LEADER, and SELECT trials established cardiovascular benefits.
SGLT2 inhibitors including empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana) are FDA-approved for T2D with cardiovascular outcomes and chronic kidney disease indications. Mechanism is sodium-glucose cotransporter 2 inhibition with renal glucose excretion. The class is particularly beneficial in heart failure with preserved or reduced ejection fraction, chronic kidney disease, and high CV risk populations. EMPA-REG OUTCOME, DAPA-HF, and CREDENCE trials established benefits.
PSI's reading: both classes hold FDA-approved positioning for T2D with overlapping and complementary indications. GLP-1 RAs offer greater HbA1c reduction and weight loss. SGLT2 inhibitors offer heart failure and CKD-specific benefits. ADA Standards of Care recommend either class as add-on to metformin in patients with established CV disease, heart failure, or CKD. Combination therapy with both classes is common in clinical practice under endocrinology or primary care guidance.
Comprehensive T2D management vs single-compound approach
Multi-factor management beyond pharmacotherapy
T2D management addresses multiple components and complications. Glycemic control reduces microvascular complications including retinopathy, nephropathy, and neuropathy. Cardiovascular risk factor management addresses macrovascular complications. Renal protection through SGLT2 inhibitors and select GLP-1 RAs reduces progression of diabetic kidney disease. Lifestyle factors including dietary pattern, physical activity, sleep, and stress contribute. Comprehensive workup per ADA Standards of Care identifies contributing factors.
Validated approaches address each component. Metformin and incretin therapies address glycemic factors. SGLT2 inhibitors address heart failure and CKD. Statins, antihypertensives, and lifestyle address cardiometabolic factors. Cardiovascular outcomes trials guide therapy selection in established CV disease. Comprehensive specialty coordination including endocrinology, primary care, cardiology, and nephrology integrates multi-factor approach.
PSI's reading: comprehensive T2D evaluation by endocrinology or primary care identifies contributing factors and matches treatment. Single-compound peptide approach without comprehensive evaluation bypasses essential workup including HbA1c monitoring, lipid panel, metabolic panel, and cardiovascular risk assessment. Validated FDA-approved options including GLP-1 receptor agonists, metformin, SGLT2 inhibitors, and lifestyle interventions form the foundation. Off-label compounded peptide use without FDA-approved framework is not validated practice.
The Compounds, Ranked by Evidence
Ordered by strength of controlled human data, not popularity.
Of the 4 peptides discussed for type 2 diabetes, three hold FDA approvals across glycemic control, weight management, and cardiovascular outcomes. Semaglutide, Tirzepatide, and Liraglutide are FDA-approved with substantial Phase 3 evidence. Retatrutide is in Phase 3 TRIUMPH-2 development at Eli Lilly. Validated standard-of-care including metformin first-line, SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin), DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin), insulin, sulfonylureas, pioglitazone, and comprehensive lifestyle interventions under endocrinology or primary care guidance dominates evidence-graded T2D medicine per ADA Standards of Care.
Semaglutide
FDA-approved Ozempic and Rybelsus for T2D. Phase 3 SUSTAIN program plus SUSTAIN-6 and SELECT cardiovascular outcomes plus FLOW renal outcomes.
Counts are PubMed-indexed papers and registered clinical trials. Scale: Strong 10+, Moderate 4–9, Limited 1–3, None 0. Methodology →
| Context | Animal Studies | Human Trials |
|---|---|---|
T2D glycemic control FDA-approved Ozempic + Rybelsus | 8 Strong incretin signaling evidence in glucose metabolism animal models. | 8 Substantial Phase 3 SUSTAIN program supporting FDA approval; HbA1c reduction approximately 1.5 to 2.0 percent. Sorli 2017 |
T2D cardiovascular outcomes FDA-approved CV indication | 4 Cardiovascular protective effects in animal models. | 6 SUSTAIN-6 trial demonstrated cardiovascular benefits in T2D with established CV disease. Marso 2016 |
T2D with chronic kidney disease FLOW trial renal outcomes | 4 Renal protective effects in animal models. | 4 FLOW trial demonstrated reduced major kidney disease events in T2D with CKD. Perkovic 2024 |
Tirzepatide
FDA-approved Mounjaro for T2D. Phase 3 SURPASS program with SURPASS-2 head-to-head superior to Semaglutide; SURPASS-CVOT ongoing.
| Context | Animal Studies | Human Trials |
|---|---|---|
T2D glycemic control FDA-approved Mounjaro indication | 8 Dual incretin signaling evidence in glucose metabolism animal models. | 8 Phase 3 SURPASS program supporting FDA approval; HbA1c reduction approximately 2.0 to 2.5 percent. Rosenstock 2021 |
T2D head-to-head efficacy SURPASS-2 vs Semaglutide | 4 Comparative incretin signaling effects. | 4 SURPASS-2 demonstrated superior HbA1c reduction versus Semaglutide. Frias 2021 |
Liraglutide
FDA-approved Victoza for T2D. Phase 3 LEADER cardiovascular outcomes and ELLIPSE pediatric T2D for adolescents 10 years and older.
| Context | Animal Studies | Human Trials |
|---|---|---|
T2D glycemic control FDA-approved Victoza indication | 8 GLP-1 signaling evidence in glucose metabolism animal models. | 8 Substantial evidence supporting FDA approval; HbA1c reduction approximately 1.0 to 1.5 percent. Marso 2016 |
T2D cardiovascular outcomes FDA-approved CV indication | 4 Cardiovascular protective effects in animal models. | 6 LEADER trial demonstrated cardiovascular benefits in T2D with established CV disease. Marso 2016 |
Pediatric T2D FDA-approved adolescent indication | 2 Pediatric-relevant pharmacology data. | 2 ELLIPSE trial supported pediatric T2D approval for adolescents 10 years and older. Tamborlane 2019 |
Retatrutide
Investigational; Phase 3 TRIUMPH-2 program at Eli Lilly. Triple GLP-1/GIP/glucagon agonist with promising Phase 2 T2D data. Not FDA-approved.
| Context | Animal Studies | Human Trials |
|---|---|---|
T2D glycemic control Phase 3 TRIUMPH-2 ongoing | 6 Triple incretin signaling evidence in glucose metabolism animal models. | 4 Phase 2 demonstrated significant HbA1c reduction in T2D populations supporting Phase 3. Rosenstock 2023 |
What's Marketed vs What's Studied
7 common claims, corrected.
“GLP-1 receptor agonists replace metformin as first-line for T2D.”
Metformin remains the FDA-approved first-line pharmacotherapy for T2D per current ADA Standards of Care for most patients. GLP-1 receptor agonists are appropriate as add-on therapy or first-line for patients with established CV disease, high CV risk, chronic kidney disease, or obesity where guidelines support GLP-1 RA preference. Combination therapy is common in clinical practice.
“Compounded GLP-1 receptor agonists are equivalent to FDA-approved Ozempic and Mounjaro.”
FDA-approved Ozempic, Rybelsus, Mounjaro, and Victoza have substantial Phase 3 evidence with quality control and regulatory oversight. Compounded peptides outside FDA-approved framework lack equivalent evidence and quality assurance. Clinical practice relies on FDA-approved products under specialty guidance per ADA Standards of Care.
“Insulin is the last resort for type 2 diabetes.”
Insulin is FDA-approved and validated for T2D when oral and injectable non-insulin therapies are insufficient or contraindicated. Insulin therapy may be initiated earlier in patients with very high HbA1c at diagnosis, severe symptoms, or specific clinical scenarios. ADA Standards of Care provides framework for insulin initiation. Insulin is not failure; it is appropriate therapy for many T2D patients.
“Retatrutide is the new go-to for T2D.”
Retatrutide Phase 2 evidence is promising with significant HbA1c reduction. The compound is investigational and in Phase 3 development at Eli Lilly within the TRIUMPH-2 program. Not FDA-approved as of 2026. Validated FDA-approved options including Semaglutide, Tirzepatide, and Liraglutide hold current evidence-graded positioning for T2D.
“SGLT2 inhibitors are only for diabetes.”
SGLT2 inhibitors hold FDA approvals across T2D, heart failure (preserved and reduced ejection fraction), and chronic kidney disease. Empagliflozin, dapagliflozin, and canagliflozin have substantial cardiovascular and renal outcomes evidence. The class is particularly beneficial in T2D patients with heart failure or CKD complications.
“I can self-treat T2D with peptides without medical supervision.”
T2D management requires comprehensive evaluation by endocrinology or primary care including HbA1c monitoring, lipid panel, metabolic panel, and cardiovascular risk assessment per ADA Standards of Care. Self-treatment with compounded peptides bypasses essential clinical assessment and validated framework. T2D is a chronic condition requiring ongoing medical management.
“Once HbA1c is normalized, T2D is cured.”
T2D is a chronic condition that may achieve remission with sufficient weight loss, lifestyle intervention, or bariatric surgery in select patients. Pharmacotherapy may be reduced or discontinued in patients achieving sustained remission under specialty guidance. Most patients require ongoing medical management. Regular monitoring is appropriate even in remission contexts.
If Considering Use, Here Is How to Be Safe
How to evaluate sources, verify quality, and find qualified physicians.
Get comprehensive T2D evaluation.
HbA1c every 3 to 6 months, fasting glucose, lipid panel, metabolic panel, BMI, blood pressure, and cardiovascular risk assessment guide treatment decisions per ADA Standards of Care.
Establish endocrinology or primary care.
Specialty evaluation determines appropriate therapy matching. Coordinated care often involves cardiology and nephrology for complications. Pediatric endocrinology manages adolescent T2D.
Match FDA-approved indications to your situation.
Metformin first-line for most. GLP-1 RA or SGLT2i for established CV disease, high CV risk, CKD, heart failure, or obesity. Specialty guidance ensures matching per ADA Standards of Care.
Optimize lifestyle and validated foundations.
Mediterranean dietary pattern, physical activity 150 minutes weekly, adequate sleep, stress management, smoking cessation, and limited alcohol form the validated foundation alongside pharmacotherapy.
Approach compounded peptides cautiously.
FDA-approved Ozempic, Rybelsus, Mounjaro, and Victoza have substantial Phase 3 evidence. Compounded peptides outside FDA-approved framework are not validated practice.
Consider cardiovascular and renal outcomes when applicable.
Select GLP-1 RAs and SGLT2 inhibitors have FDA-approved cardiovascular and renal outcomes indications. Cardiology and nephrology coordination is appropriate for complications.
The regulatory landscape for T2D peptides is rapidly evolving. Semaglutide approvals across Ozempic and Rybelsus continue to expand with cardiovascular outcomes (SUSTAIN-6, SELECT) and renal outcomes (FLOW) indications. Tirzepatide Mounjaro approval has driven major commercial adoption with SURPASS-CVOT ongoing. Retatrutide Phase 3 TRIUMPH-2 program at Eli Lilly is ongoing with anticipated readouts. Compounded GLP-1 receptor agonists have faced regulatory scrutiny during commercial supply normalization. PSI tracks these developments and updates this page as material changes occur.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Common Questions
Are any peptides FDA-approved for type 2 diabetes?
Yes. Three peptides hold FDA approvals for type 2 diabetes. Semaglutide is FDA-approved as Ozempic (subcutaneous) and Rybelsus (oral) for T2D. Tirzepatide is FDA-approved as Mounjaro for T2D. Liraglutide is FDA-approved as Victoza for adult T2D and pediatric T2D in adolescents 10 years and older. Retatrutide is investigational with Phase 3 TRIUMPH-2 program at Eli Lilly. All three FDA-approved compounds have substantial Phase 3 evidence.
Should I see an endocrinologist or primary care for T2D?
Primary care often manages initial T2D evaluation and routine management for many patients. Endocrinology specialty manages complex T2D, brittle diabetes, hypoglycemia, multiple complications, or insulin pump therapy. Cardiology coordinates with endocrinology for cardiovascular risk reduction. Nephrology coordinates for diabetic kidney disease. ADA Standards of Care provides framework for care coordination. Pediatric endocrinology manages adolescent T2D.
What is the comprehensive evaluation for T2D?
Comprehensive T2D evaluation per ADA Standards of Care includes HbA1c (every 3 to 6 months), fasting plasma glucose, lipid panel (total cholesterol, LDL, HDL, triglycerides), metabolic panel (creatinine, eGFR, electrolytes), liver function tests, urine microalbumin, BMI, blood pressure, and cardiovascular risk assessment. Annual evaluations include eye examination for retinopathy, foot examination for neuropathy, and assessment of complications. Vaccinations are addressed per ADA recommendations.
How do GLP-1 receptor agonists work for T2D?
GLP-1 receptor agonists are synthetic peptides resistant to DPP-4 degradation that activate GLP-1 receptors. Mechanism includes glucose-dependent insulin secretion enhancement, glucagon suppression, gastric emptying delay, and central appetite reduction. Glycemic effects produce HbA1c reduction approximately 1.0 to 2.5 percent depending on compound. Weight reduction is typically observed. Cardiovascular outcomes benefits are established for select compounds in T2D with established CV disease.
What is the difference between Semaglutide and Tirzepatide for T2D?
Both compounds are FDA-approved for T2D with substantial Phase 3 evidence. Semaglutide is a GLP-1 receptor agonist (single receptor) approved as Ozempic and Rybelsus. Tirzepatide is a dual GIP/GLP-1 receptor agonist approved as Mounjaro. SURPASS-2 head-to-head trial demonstrated Tirzepatide superior HbA1c reduction over 40 weeks. Semaglutide has earlier cardiovascular outcomes evidence (SUSTAIN-6, SELECT) and oral formulation availability.
Why is metformin still the first-line for T2D?
Metformin remains FDA-approved first-line pharmacotherapy for T2D per current ADA Standards of Care for most patients. Reasons include decades of safety data, low cost with generic availability, established cardiovascular safety, modest weight neutrality, and effective HbA1c reduction. GLP-1 receptor agonists or SGLT2 inhibitors may be first-line or earlier add-on for patients with established CV disease, high CV risk, chronic kidney disease, heart failure, or obesity per current guidelines.
What about SGLT2 inhibitors for T2D and complications?
SGLT2 inhibitors including empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana) are FDA-approved for T2D with cardiovascular outcomes and chronic kidney disease indications. Mechanism is sodium-glucose cotransporter 2 inhibition with renal glucose excretion. Cardiovascular and renal outcomes benefits are substantial. The class is particularly beneficial in T2D patients with heart failure (preserved or reduced EF), chronic kidney disease, and high CV risk populations.
What are the side effects of GLP-1 receptor agonists?
Common GLP-1 receptor agonist side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, and reduced appetite. GI symptoms are most common during dose titration. Less common effects include pancreatitis (boxed warning across class), gallbladder disease, and rare thyroid C-cell tumors in animal models. Contraindications include personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Pregnancy and certain GI conditions affect prescribing.
Can pediatric patients use GLP-1 receptor agonists for T2D?
Liraglutide (Victoza) is FDA-approved for pediatric T2D in adolescents 10 years and older. ELLIPSE Phase 3 trial supported the pediatric indication. Comprehensive pediatric endocrinology evaluation including growth assessment, pubertal staging, and cardiovascular risk evaluation is appropriate. Pediatric T2D management includes lifestyle intervention, metformin (often first-line), and Liraglutide as additional FDA-approved option. Other GLP-1 RAs are not FDA-approved for pediatric T2D.
Should I take Ozempic or Mounjaro?
Ozempic (Semaglutide) and Mounjaro (Tirzepatide) are both FDA-approved for T2D with different mechanisms (GLP-1 vs dual GIP/GLP-1). Both achieve substantial HbA1c reduction. SURPASS-2 demonstrated Mounjaro superior to Ozempic in HbA1c. Ozempic has SUSTAIN-6 and SELECT cardiovascular outcomes evidence. Patient selection considers individualized factors including cardiovascular risk, formulation preference, dose titration tolerability, insurance coverage, and access under endocrinology or primary care guidance.
What about insulin for T2D?
Insulin is FDA-approved and validated for T2D when non-insulin therapies are insufficient or contraindicated. Basal insulins include glargine (Lantus, Basaglar, Toujeo), detemir (Levemir), and degludec (Tresiba). Bolus insulins include lispro (Humalog), aspart (Novolog), and glulisine (Apidra). Premixed formulations are available. Insulin may be initiated earlier in T2D patients with very high HbA1c at diagnosis or severe symptoms. ADA Standards of Care provides framework for insulin initiation.
Are these peptides legal in the United States?
Semaglutide is FDA-approved as Ozempic and Rybelsus by Novo Nordisk by prescription. Tirzepatide is FDA-approved as Mounjaro by Eli Lilly by prescription. Liraglutide is FDA-approved as Victoza by Novo Nordisk by prescription. Retatrutide is investigational; access is through clinical trial enrollment. Compounded GLP-1 receptor agonists are available through 503A pharmacies during commercial supply shortages but represent non-validated practice for indications outside FDA-approved scope. Always work with a licensed prescriber.
How long does it take for GLP-1 receptor agonists to work in T2D?
Glycemic effects of GLP-1 receptor agonists develop over the first weeks of therapy with full HbA1c effect typically achieved at 12 to 16 weeks. Weight effects develop over months. Dose titration over 16 weeks is standard for Semaglutide and over 20 weeks for Tirzepatide to manage GI side effects. Cardiovascular outcomes benefits develop over multi-year treatment in indicated populations. Comprehensive monitoring under specialty guidance ensures appropriate dose titration.
Should lifestyle factors be addressed alongside T2D peptide therapy?
Yes. Comprehensive lifestyle interventions remain foundational for T2D alongside pharmacotherapy. Mediterranean dietary pattern provides substantial validated cardiometabolic outcomes evidence. Physical activity 150 minutes moderate intensity weekly per ADA improves insulin sensitivity. Adequate sleep 7 to 9 hours supports metabolic regulation. Stress management addresses cortisol effects. Smoking cessation reduces cardiovascular risk. Limited alcohol consumption supports metabolic outcomes. Endocrinology or primary care guidance integrates lifestyle and pharmacotherapy.
What about T2D remission and bariatric surgery?
T2D remission is achievable in select patients through sufficient weight loss, comprehensive lifestyle intervention, or bariatric surgery. Bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy) demonstrates substantial T2D remission rates in eligible patients. ADA Standards of Care recommends consideration of bariatric surgery in T2D patients with BMI 35 or higher (or 30 or higher with inadequate glycemic control). Endocrinology, primary care, and bariatric surgery coordination ensures appropriate evaluation. Most patients require ongoing monitoring even in remission.
What questions should I ask my doctor about peptides for T2D?
Ask: (1) What is my comprehensive T2D evaluation including HbA1c, lipid panel, metabolic panel, and cardiovascular risk? (2) Is metformin appropriate as first-line, or do I have specific indications for GLP-1 RA or SGLT2 inhibitor first-line? (3) For my situation, what FDA-approved options apply (Semaglutide, Tirzepatide, Liraglutide, oral Rybelsus)? (4) Are cardiovascular outcomes considerations relevant? (5) How do contraindications apply (medullary thyroid carcinoma history, pancreatitis history, pregnancy planning)? (6) What is my realistic timeline and monitoring plan?
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.